Maplight Therapeutics
Clinical trials sponsored by Maplight Therapeutics, explained in plain language.
-
New schizophrenia drug shows promise in Long-Term safety trial
Disease control Recruiting nowThis study is testing a new drug called ML-007C-MA for adults with schizophrenia. The goal is to see if it is safe and works well over a full year. About 500 people who have recently been in a related study or are new to the trial will take the drug twice daily. Researchers will …
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill aims to quiet Alzheimer's psychosis
Symptom relief Recruiting nowThis Phase 2 study tests an experimental drug, ML-007C-MA, to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 300 participants aged 55 to 90 will receive either the drug or a placebo. The main goal is to measure changes in psycho…
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New hope for Alzheimer's psychosis: Long-Term drug trial underway
Symptom relief Recruiting nowThis study is testing the long-term safety of a drug called ML007C-MA for people with Alzheimer's disease who also have hallucinations and delusions. About 210 adults who completed a previous study will take the drug twice daily for up to 52 weeks. The goal is to see if the drug …
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC